Primary microparticles and agglomerates of morphine for nasal insufflation

被引:28
作者
Russo, Paola
Sacchetti, Cecilia
Pasquali, Irene
Bettini, Ruggero
Massimo, Gina
Colombo, Paolo
Rossi, Alessandra
机构
[1] Univ Parma, Dept Pharm, I-43100 Parma, Italy
[2] Univ Salerno, Dept Pharmaceut Sci, I-84084 Salerno, Italy
关键词
in vitro models; agglomerates; morphine; powder technology; nasal drug delivery; microparticles;
D O I
10.1002/jps.20604
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aim of this work was to study the characteristics of powders of morphine HCl suitable for nasal administration to be employed for pain treatment as alternative to injection. Primary microparticles of morphine were prepared by spray drying of aqueous drug solutions using sugars or sugar derivatives as drying protectors and particle shapers. The spray drying procedure modified morphine crystallinity making the substance amorphous and affecting its stability in dependence on the excipient employed. A tendency of the spray-dried powders to turn to varying degrees of yellow was observed. Tumbling the powder in a rotating pan allowed the agglomeration of the primary microparticles. Agglomerates were also obtained by tumbling a mixture of morphine crystals and spray-dried microparticles of excipients, with advantages for the stability of the preparation. A nasal device quantitatively insufflated all the morphine agglomerates. The in vitro transport of morphine through rabbit nasal mucosa was faster using nasal powders than with the saturated solution of morphine. Lactose was the most effective excipient for agglomerate manufacturing and delivery of spray-dried morphine. The agglomerates of morphine crystals mixed with mannitol/lecithin microparticles showed superior stability. However, the drug permeation through rabbit mucosa was slower than with spray-dried morphine microparticle agglomerates. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:2553 / 2561
页数:9
相关论文
共 16 条
[1]  
ACHARI RG, 2000, Patent No. 6677346
[2]  
BEHL CR, 2002, Patent No. 6451848
[3]   Biovector™ nanoparticles improve antinociceptive efficacy of nasal morphine [J].
Betbeder, D ;
Sperandio, S ;
Latapie, JP ;
de Nadai, J ;
Etienne, A ;
Zajac, JM ;
Frances, B .
PHARMACEUTICAL RESEARCH, 2000, 17 (06) :743-748
[4]  
BOURGET P, 1995, INT J CLIN PHARM TH, V33, P588
[5]   Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles [J].
Dyer, AM ;
Hinchcliffe, M ;
Watts, P ;
Castile, J ;
Jabbal-Gill, I ;
Nankervis, R ;
Smith, A ;
Illum, L .
PHARMACEUTICAL RESEARCH, 2002, 19 (07) :998-1008
[6]   Initial pharmacokinetic, safety and efficacy evaluation of nasa morphine gluconate for breakthrough pain in cancer patients [J].
Fitzgibbon, D ;
Morgan, D ;
Dockter, D ;
Barry, C ;
Kharasch, ED .
PAIN, 2003, 106 (03) :309-315
[7]   TRANSNASAL BUTORPHANOL - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN ACUTE PAIN MANAGEMENT [J].
GILLIS, JC ;
BENFIELD, P ;
GOA, KL .
DRUGS, 1995, 50 (01) :157-175
[8]  
Hussain AA, 1984, US Patent, Patent No. [4464378, US4464378]
[9]   Intranasal delivery of morphine [J].
Illum, L ;
Watts, P ;
Fisher, AN ;
Hinchcliffe, M ;
Norbury, H ;
Jabbal-Gill, I ;
Nankervis, R ;
Davis, SS .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :391-400
[10]  
ILLUM L, 1997, Patent No. 5629011